Isentio AS, founded in 2005, develops software based on advanced DNA analysis methods created by founders Øyvind Kommedal, Øystein Sæbø and CEO Bjarte Karlsen. Its RipSeq® software is a web-based sequence analysis solution for identification of multiple bacteria after direct sequencing of clinical patient samples. RipSeq is in use at hospitals in Europe and the USA. The company intends to use new funding to grow sales, marketing and support and to accelerate development of new application areas. Isentio has already commercialized its core product and remains research-driven. The company is based in Bergen, Norway.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2011